{"id":"NCT04620811","sponsor":"Allakos Inc.","briefTitle":"An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)","officialTitle":"A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-03","primaryCompletion":"2023-05-15","completion":"2023-07-07","firstPosted":"2020-11-09","resultsPosted":"2024-04-18","lastUpdate":"2024-04-22"},"enrollment":159,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Gastritis","Eosinophilic Duodenitis"],"interventions":[{"type":"DRUG","name":"lirentelimab","otherNames":["AK002"]}],"arms":[{"label":"3.0 mg/kg of Lirentelimab (AK002)","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.","primaryOutcome":{"measure":"The Safety and Tolerability of Lirentelimab by Evaluating Adverse Events Assessed Using the CTCAE Version 5.0","timeFrame":"Through study completion, up to 21 months","effectByArm":[{"arm":"Main Study Placebo to Extension Study 3.0 mg/kg of Lirentelimab (AK002)","deltaMin":66,"sd":null},{"arm":"Main Study Active to Extension Study 3.0 mg/kg of Lirentelimab (AK002)","deltaMin":75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":75},"commonTop":["Infusion related reaction","Corona virus infection","Diarrhoea","Abdominal pain","Nausea"]}}